Novartis Smoker’s Cough Treatment Beats Glaxo’s Advair in Trial

Patients taking Novartis AG’s experimental once-daily treatment for smoker’s cough showed a significant improvement in lung function over those on an existing medicine marketed by GlaxoSmithKline (GSK), which is also developing a successor drug.
Bloomberg